Ixmyelocel-T

N/A

Report date: 2025/09/04 20:00:08

Base Information

Drug NameIxmyelocel-T
Drug Alias NameTissue repair stem cell therapy-Vericel CorporationCRC therapy-Vericel CorporationVascular Repair Cells-Vericel CorporationCardiac Repair Cells-Vericel CorporationTissue Repair Cells-Vericel Corporation +[9] 
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsFractures, BoneIschemiaPeripheral Arterial Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVericel Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of MichiganVericel Corp
Active IndicationsN/A
Inactive IndicationsFractures, BoneIschemiaPeripheral Arterial Disease +[6] 

Other Information

ATC CodeN/A
Related LinksN/A